INTRODUCTION AND OBJECTIVES: Overall Survival for
Muscle Invasive Bladder Cancer (MIBC) with Radical Cystectomy (RC) is improved with neoadjuvant chemotherapy and surgery in high-volume centers. However, concentration of care inadvertently increases the average travel distance for patients who may have a post-RC complication. Using data from the National Cancer Data Base (NCDB), we evaluated the association between increasing travel distance in patients undergoing RC and the likelihood of receiving high volume care, neoadjuvant chemotherapy and overall survival.
METHODS: Data were obtained from NCDB 2004-13. Patients had MIBC (T2-T4a, N0, M0) treated with RC. Distance to treating facility was examined in 3 categories (<12.5, 12.5-49, 50-250 miles) . Multivariate logistic regression analysis was preformed to examine the interaction between distance and overall survival, then to test receipt of neoadjuvant chemotherapy. Multinomial regression examined the interaction between travel distance and RC volume tertiles (<3, 3-6, >6 per year). RESULTS: 11,059 patients treated with RC identified, including 2609 that had neoadjuvant chemotherapy. Hazard ratios for overall survival, receipt of neoadjuvant chemotherapy, as well as volume of RC are presented in Table 1 . Overall survival was not associated with travel distance. As distance to facility increased, so did the likelihood that a patient received neoadjuvant chemotherapy. Increase in distance was also associated with facilities that had high volumes of RC.
CONCLUSIONS: As distance to treatment facility increased, the likelihood that a patient would receive neoadjuvant chemotherapy or have surgery at a high volume center also increased, supporting the relationship between concentration of care and quality. Nevertheless, overall survival was not affected by distance.
Source of Funding: None

MP76-06 TRENDS IN USE OF ANDROGEN DEPRIVATION THERAPY WITH RADIATION IN HIGH AND VERY HIGH RISK PROSTATE CANCER PATIENTS
INTRODUCTION AND OBJECTIVES: For men with high and very high risk prostate cancer, level I evidence supports the use of androgen deprivation therapy (ADT) with radiation to prolong diseasespecific and overall survival. However, not all patients receive ADT with radiotherapy. We sought to evaluate trends and factors associated with ADT use with radiation therapy for clinically localized high and very high risk prostate cancer.
METHODS: We identified patients diagnosed with high or very high risk prostate cancer in the National Cancer Database from 2004-2013 and underwent external beam radiotherapy (EBRT), brachytherapy (BT) or combined EBRT and BT. ADT use was defined as receipt of ADT prior to or at the time of radiation therapy. Trends in ADT use were assessed and multivariable logistic regression was used to evaluate associations between demographic and clinical factors and the receipt of ADT CONCLUSIONS: Use of ADT in patients undergoing radiotherapy for high or very high risk prostate cancer has increased over the past decade in patients undergoing EBRT and combination EBRT and BT. However, more than one third of these patients do not receive ADT, which represents an opportunity for quality improvement initiatives to impact the quality of prostate cancer care. INTRODUCTION AND OBJECTIVES: Assessment of surgical risk is integral to patient counseling and shared clinical decisionmaking. The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) surgical risk calculator is an easily accessible, online tool for predicting surgical outcomes after a variety of procedures. Little is known of the tool's applicability to urologic surgery. We sought to evaluate the predictive value of the calculator in a tertiary referral cohort of patients undergoing robot-assisted partial nephrectomy (RAPN).
METHODS: We queried our prospectively maintained multiinstitutional database of RAPN (n¼1260) from 2008 to 2016. Preoperative details of 300 randomly selected patients were entered into the calculator. The predicted rates of complications were compared with the actual rates of observed complications. Validation of the calculator was assessed by receiver-operator area under the curve (AUC) for discrimination and Brier score (BS) for calibration. Calculated BS was also compared to a null model (null-BS); a BS lower than the null model indicates stronger predictive power for that individual outcome where a BS of zero indicates perfect prediction.
RESULTS: The observed rate of any complication in our cohort was 14%, comparable with that reported in the literature, while the mean predicted rate of any complication was 5.42%. The calculated AUC for any complications was 0.51. Our cohort demonstrated a serious complication (Clavien Score 3) rate of 3.67%, lower than the predicted rate of 4.89% (AUC 0.55). The majority of the captured complications had a low BS, indicative of good calibration. However, the calculated AUC was low for all outcomes, indicating poor discrimination ability. Venous thromboembolism (VTE) and readmission had the highest AUCs -0.67 and 0.69, respectively. CONCLUSIONS: The ACS-NSQIP risk calculator poorly predicted most complications after RAPN. The model had marginal accuracy for predicting VTE and readmissions, and good accuracy for predicting the rate of serious complications, but it lacked the power to discriminate which patients were at risk to have such outcomes. These findings suggest the need for a more tailored outcome prediction model to accurately assist surgeons in counseling patients undergoing RAPN. . Approximately 30% of men with CS1 NSGCT are liable to relapse on AS. Pathological risk factors (PRF) may identify men at higher risk for relapse. Our aim was to evaluate trends in managing CS1 NSGCT and to examine the influence of PRF.
Source of Funding: None
METHODS: We used national cancer database (NCDB), 2004 to 2013; we examined AS, adjuvant Chemotherapy (ACT) and adjuvant retroperitoneal lymph node dissection (RPLND) using cross tabulation and trend analysis. We assessed PRF including, lympho-vascular invasion (LVI) and the presence of embryonal carcinoma (EC). We further examined the impact of CS1 sub-staging, IA, IB and IS, as defined by the TNM classification (UICC 2009 7th Ed.). Differences in overall survival (OS) were observed by treatment modality, based on log rank test.
RESULTS: 12,211 men were classified as CS1 NSGCT in NCDB; of these 2,484 men were LVI +ve, 4,686 were LVI -ve (5041 had missing LVI data); 2,624 men had EC. Trend analyses (Fig.1) showed a stable utilization of AS (p ¼ 0.310), a rising preference for ACT (p <0.001) and a declining utilization of RPLND (p <0.001). Analysis of PRF showed 40% of LVI +ve men had ACT vs 18% of LVI -ve men, Fig  2. The presence of EC increased the chances for ACT (32% vs 22% in those with no EC). Analysis of CS1 sub-staging showed 37% of IB and 29% of IS had ACT vs only 15% of IA sub-group. RPLND use was not influenced by sub-staging or LVI status.
CONCLUSIONS: AS remains underutilized in CS1 NSGCT. We observed a slow but steady rise towards more ACT usage and a declining utilization of RPLND. Utilization of ACT was greatly influenced by PRF. We believe that PRF and subgrouping of CS1 may be influencing decision making for men with CS1 NSGCT disease that is amenable to AS.
